Canadian biopharmaceutical company Lorus Therapeutics Inc. (LOR.TO,LRUSF.PK) posted a narrower loss in the third quarter.
The company posted third-quarter net loss of C$1.0 million or C$0.05per share, narrower than than C$1.5 million or C$0.10 per share last year. Lorus Therapeutics attributed the wider net loss mainly to higher general and administrative, and research and development expenditures.
The company did not generate any revenues in both the quarters.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.